Stryker won an expanded CE Mark for its Trevo stent retriever, a thrombectomy device used as a front-line treatment for acute ischemic stroke.

The expanded indication increases the previously cleared treatment window by 18 hours to 24 hours, following a similar action by the FDA in February.

Clinical trial data showed that patients treated with the Trevo retriever in the six- to 24-hour window were almost four times as likely to be functionally independent at 90 days post stroke.